Skip to main content

Table 2 Toxicities during DLT observation period

From: Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

Dose level (MBq)

N

Fever

Vomiting

Anxiety

Pruritus

Hypothermia

ALT

Bilirubin

AST

Platelets

ANC

Lymphopenia

Grade

 

1

1

2

1

1

2

1

2

3

1

1

2

3

1

2

3

4

1

2

3

4

3

370

3

      

1

      

1

       

1

740

3

 

1

        

1

    

1

     

1

1110

6

1

2

   

1

2

1

1

 

2

1

1

1

  

1

 

1

  

2

1480

3

 

1

        

1

  

1

 

1

0

 

1

   

1850

6

1

1

1

   

1

   

1

    

1

1

  

2

1

 

2220

4

   

1

1

 

3

  

1

3

    

1

2

  

1

1

1

2590

6

 

1

    

1

    

1

 

1

1

 

1

 

1

 

1

1

2960

5

  

1

    

1

        

1

   

1

1

Total

36

2

6

2

1

1

1

8

2

1

1

8

2

1

4

1

4

6

0

3

3

4

7

  1. DLT dose-limiting toxicity, ALT alanine transaminase, AST aspartate aminotransferase, ANC absolute neutrophil count,
  2. N: number receiving at least one therapeutic dose of radioiodinated omburtamab
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us